...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Abstract - first example of a "curative" effect?

Interesting for sure

The resistance to BETi’s appears to be linked to increased NfKb which when inhibited restores sensitivity to BETi’s

check out latest PubMed abstract on Brd4, which wasnt JQ1


New Message
Please login to post a reply